NGEN
NervGen Pharma Corp.
NASDAQ: NGEN · HEALTHCARE · BIOTECHNOLOGY
$3.63
-3.20% today
Updated 2026-04-30
Market cap
$311.58M
P/E ratio
—
P/S ratio
—
EPS (TTM)
$-0.45
Dividend yield
—
52W range
$2 – $6
Volume
0.2M
NervGen Pharma Corp. (NGEN) Financial statements
SEC filings — annual and quarterly data.
Income statement — annual
| Item | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 |
| Revenue growth (YoY) | — | — | — | — |
| Cost of revenue | $84919.00 | $109404.00 | $58231.00 | — |
| Gross profit | $-84919.00 | $-109404.00 | $-58231.00 | — |
| Gross margin | — | — | — | — |
| R&D | $12.22M | $6.04M | $10.89M | $13.91M |
| SG&A | $6.34M | $9.63M | $9.34M | $11.17M |
| Operating income | $-16.99M | $-13.41M | $-17.33M | $-25.08M |
| Operating margin | — | — | — | — |
| EBITDA | $-14.82M | $-16.78M | $-16.62M | $-5.65M |
| EBITDA margin | — | — | — | — |
| EBIT | $-14.91M | $-16.89M | $-16.68M | $-5.71M |
| Interest expense | $379619.00 | $0.00 | — | — |
| Income tax | — | — | — | — |
| Effective tax rate | 0.0% | 0.0% | 0.0% | 0.0% |
| Net income | $-15.29M | $-16.89M | $-16.68M | $-44.12M |
| Net income growth (YoY) | — | -10.5% | +1.2% | -164.5% |
| Profit margin | — | — | — | — |